Procurement Shortage of Regenerative Medicine-Related Materials
First written in FY2021. 1 of 4 entries say "Worsened", first in FY2022. Latest entry: FY2025.
0 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「For materials procurement, we are again reviewing suppliers, establishing a communication system with suppliers and building a strict inventory management system. We are also ensuring that multiple alternative products can always be supplied. However, if demand in fields such as regenerative medicine and biopharmaceuticals rises sharply, transportation conditions become uncertain due to the international situation, or an event similar to the COVID-19 pandemic occurs, supplies may become scarce, potentially delaying or halting our contract processing services.」
The policy of addressing risks through supplier reviews, a communication system, inventory management and securing multiple alternative products remains in place. The risk of supply shortages due to a sharp increase in demand, the international situation and infectious-disease-like events also remains. - FY2023MitigatedAnnual report
「For materials procurement, we are again reviewing suppliers, establishing a communication system with suppliers and building a strict inventory management system. We are also ensuring that multiple alternative products can always be supplied.」
Measures to review suppliers, establish a communication system, manage inventory strictly and secure multiple alternative products have been put into practice. The risk of supply shortages due to a sharp increase in demand, the international situation and infectious-disease-like events remains. - FY2022WorsenedAnnual report
「In 2022, supply chain and other risks increased due to China's zero-COVID policy and the international situation surrounding Russia and Ukraine. We were also affected in some areas, including by the time required to secure supplies necessary for our contract processing services.」
In addition to the previous shortage of laboratory supplies, supply and transportation risks arising from China's zero-COVID policy and the situation involving Russia and Ukraine emerged, and delays in securing necessary supplies also occurred in 2022. - FY2021First statedAnnual report
「In 2021, amid global research and development of vaccines and other products in response to the spread of COVID-19, a global shortage of laboratory supplies occurred. We were also affected in some areas, including by the time required to secure supplies necessary for our contract processing services.」
The global shortage of laboratory supplies did in fact delay the procurement of necessary supplies. We are reviewing suppliers, strengthening communication with suppliers and establishing an inventory management system.